title: A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with β-naphthoflavone, phenobarbital and rifampicin.
abstract: U.S. FDA and EMEA guidance recommend that the preferred in vitro model for cytochrome P450 induction testing is human hepatocytes coupled with acceptable inducers as controls. However, there are surprisingly few published studies characterizing this model system for dose and time-dependence response to model inducing compounds. The concentration-dependent response and time-course for the induction of CYP1A2, CYP2B6 and CYP3A4 by inducing agents β-naphthoflavone, phenobarbital and rifampicin, respectively were examined in two or more donors using multiple end-points (mRNA, enzyme activity and Western blot analysis). Depending on the endpoint, exposure time for maximal response of CYP induction potential for the three enzymes ranged from 24 to 72 hours. Of the concentrations of BNF, PB and RIF tested, those which gave the maximal response were found to be 33 µM, > 2 mM and 10 µM, respectively.
authors.affiliation: BD Biosciences Discovery Labware, 6 Henshaw Street, Woburn, MA 01801, USA. George_Zhang@bd.com
authors.forename: J G
authors.initials: JG
authors.lastname: Zhang
authors.forename: Thuy
authors.initials: T
authors.lastname: Ho
authors.forename: Alanna L
authors.initials: AL
authors.lastname: Callendrello
authors.forename: Charles L
authors.initials: CL
authors.lastname: Crespi
authors.forename: David M
authors.initials: DM
authors.lastname: Stresser
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000096:biosynthesis* / Q000235:genetics; D001681:Biological Assay / Q000592:standards; D015153:Blotting, Western; D002478:Cells, Cultured; D019388:Cytochrome P-450 CYP1A2 / Q000096:biosynthesis* / Q000235:genetics; D065702:Cytochrome P-450 CYP2B6; D051544:Cytochrome P-450 CYP3A / Q000096:biosynthesis* / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D023381:Endpoint Determination; D004790:Enzyme Induction; D022781:Hepatocytes / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D010089:Oxidoreductases, N-Demethylating / Q000096:biosynthesis* / Q000235:genetics; D010634:Phenobarbital / Q000494:pharmacology*; D012333:RNA, Messenger / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012293:Rifampin / Q000494:pharmacology*; D013379:Substrate Specificity; D013997:Time Factors; D019324:beta-Naphthoflavone / Q000494:pharmacology*
chemical_list: D012333:RNA, Messenger; D019324:beta-Naphthoflavone; D001189:Aryl Hydrocarbon Hydroxylases; C504573:CYP1A2 protein, human; C585599:CYP2B6 protein, human; D019388:Cytochrome P-450 CYP1A2; D065702:Cytochrome P-450 CYP2B6; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D010089:Oxidoreductases, N-Demethylating; D012293:Rifampin; D010634:Phenobarbital